ASH 2018 | Bretuximab vedotin plus re-induction chemotherapy for CD30+ R/R AML
Bretuximab vedotin plus re-induction chemotherapy is under investigation for the treatment of CD30+ relapsed/refractory acute myeloid leukemia (AML). Amir Fathi, MD, MPH, of the Massachusetts General Hospital, Boston, MA, discusses the results of this Phase I study (NCT01830777), highlighting tolerability, safety and response data. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up